Table 2.

Pre- and post-rituximab relapse details.

	Total (N = 37)	AQP4-IgG-positive (N = 27)	Seronegative (N = 10)
Relapse severity pre-rituximab, N (%)
Mild	9 (18%)	6 (16%)	3 (25%)
Moderate	33 (66%)	26 (68%)	7 (58%)
Severe	8 (16%)	6 (16%)	2 (17%)
Relapse severity post-rituximab
Mild	17 (65%)	12 (80%)	5 (45.5%)
Moderate	9 (35%)	3 (20%)	6 (55.5%)
Severe	0	0	0
Relapses within 6 months of starting rituximab, N (% of relapses post-rituximab)	4 (15%)	3 (20%)	1 (9%)
Post-rituximab relapses associated with B-cell reconstitution, N (%)	7 (27%)	4 (27%)	3 (27%)
mRS pre-rituximab, median (IQR)	2 (1–3)	2 (1–3)	2 (2–3)
mRS at end of follow-up post-rituximab, median (IQR)	1 (1–2)	1 (0–2)	1 (1–2)